Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 9;26(9):e1609–e1618. doi: 10.1002/onco.13822

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Association of RDI with OS in studies of FOLFOX‐, FOLFIRI‐, or FOLFIRINOX‐based and carboplatin‐based regimens. *, Kobayashi et al. (2019) evaluated 5‐flurouracil infusion as part of an evaluation of constituents of FOLFIRINOX. Abbreviations: CI, confidence interval; CRC, colorectal cancer; FOLFIRI, folinic acid (leucovorin), fluorouracil (5‐FU), and irinotecan; FOLIRINOX, folinic acid (leucovorin), fluorouracil (5‐FU), irinotecan, and oxaliplatin; HR, hazard ratio; mFOLFOX6, modified folinic acid (leucovorin), fluorouracil (5‐FU), and oxaliplatin (six cycles postoperative); NSCLC, non‐small cell lung cancer; OS, overall survival; RDI, relative dose intensity; seTE, standard error of treatment effect; TE, treatment effect.